Advertisement

Management of Cirrhotic Patients After Successful HCV Eradication

  • Ryan M. KwokEmail author
  • Tram T. Tran
Liver (J Bajaj, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Liver

Opinion statement

Chronic hepatitis C (HCV) is a hepatotropic virus which, when untreated, can lead to progressive inflammation and fibrosis resulting in cirrhosis, hepatocellular carcinoma (HCC), and decompensations related to end-stage liver disease. The relatively recent introduction of all oral, interferon-free, direct-acting antiviral medications against HCV has transformed the management of these patients. Previous treatment regimens were prolonged, poorly tolerated, and frequently did not result in cure. Current therapies achieve sustained viral response (SVR) in the vast majority of patients including those with decompensated liver disease; a previously challenging population to treat. These successes will result in significant numbers of cirrhotic patients requiring management after SVR. Although many complications of cirrhosis are improved in this setting, regular follow-up of HCC, esophageal varices, and other sequelae of cirrhosis will be necessary. This chapter will review the management of cirrhosis in HCV patients achieving cure.

Keywords

Hepatitis C Cirrhosis Decompensated liver disease Gastroesophageal varices Ascites Hepatic encephalopathy Hepatocellular carcinoma Sustained virologic response Portal hypertension 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ryan M. Kwok declares no conflict of interest.

Tram T. Tran declares grants and personal fees from Gilead Sciences, BMS, AbbVie, Merck, and Janssen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333.CrossRefPubMedGoogle Scholar
  2. 2.
    El-Serag H, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767–75.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001;161(18):2231–7.CrossRefPubMedGoogle Scholar
  5. 5.
    http://www.hcvguidelines.org. Accessed on November 23, 2016.
  6. 6.
    George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffman J, Di Bisceglie AM. Clinical, Virologic, histologic, and biochemical outcomes after Successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–38.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, et al. Outcomes of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–44.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Singal AG, Volk ML, Jensen D, Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastro Hep. 2010;8:280–8.CrossRefGoogle Scholar
  9. 9.
    EASL Recommendations on Treatment of Hepatitis C 2015.Google Scholar
  10. 10.
    • Deterding K, H€oner zu Siederdissen C, Port K, Solbach P, Sollik P, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42:889–901. Real world study of patients with advanced cirrhosis treated with interferon free, DAA regimens and demonstrating an improvement across a spectrum of biochemical parameters. These data suggest the need for liver transplantation may be reduced after treatment with these regimenCrossRefPubMedGoogle Scholar
  11. 11.
    Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained Virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683–94.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gambato M, Perez-del-Pulgar S, Hedskog C, Svarovskia ES, et al. Hepatitis C virus RNA persists in liver explants of most patients awaiting liver transplantation treated with an interferon-free regimen. Gastroenterology. 2015;151(4):633–6.CrossRefGoogle Scholar
  13. 13.
    Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, et al. Mechansisms of spontaneous resolution of rat liver fibrosis. J Clin Invest. 1998;102(3):538–49.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pinzani M. Liver fibrosis in the post-HCV era. Semin Liv Dis. 2015;35:157–65.CrossRefGoogle Scholar
  15. 15.
    Kisseleva T, Brenner DA. Fibrogenesis of parenchymal organs. Proc Am Thorac Soc. 2008;5:338–42.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Desmet VJ. Comments on cirrhosis reversal. Dig and Liv Dis. 2005;37:909–16.CrossRefGoogle Scholar
  17. 17.
    Chhatwal J, Samu S, Kues B, Ayer T, Roberts MS, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2016; doi: 10.1002/hep.28926.PubMedGoogle Scholar
  18. 18.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide; sources, methods, and major patters in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.CrossRefPubMedGoogle Scholar
  19. 19.
    Fattowich G, Strffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis incidence and risk factors. Gastroenterology. 2004;127(5 suppl 1):S35–50.CrossRefGoogle Scholar
  20. 20.
    Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.CrossRefPubMedGoogle Scholar
  22. 22.
    • van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2016;66(3):485–93. This study is among the largest and most recent to analyze the risk of liver cancer after eradication of HCV. Although recommendations remain for continued HCC surveillance after SVR, identification of higher risk patients (advanced age, biochemical evidence of severe liver disease, and the presence of diabetes mellitus) should aid in future risk stratification and possible modification of surveillance guidelinesCrossRefPubMedGoogle Scholar
  23. 23.
    El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained Virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64:130–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726–36.CrossRefPubMedGoogle Scholar
  25. 25.
    Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–33.CrossRefPubMedGoogle Scholar
  26. 26.
    ANRS collaborative study group of hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734–40.CrossRefGoogle Scholar
  27. 27.
    García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57:458.CrossRefPubMedGoogle Scholar
  28. 28.
    Castera L, Vergniol J, Foucher J, Bail BL, Chanteloup E, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Singh S, Fujii LL, Murad MH, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastro Hepatol. 2013;11:1573–84.CrossRefGoogle Scholar
  30. 30.
    Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Colecchia A, Montrone L, Scaioli E, Bacchi-Reggiani ML, Colli A, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology. 2012;143(3):646–54.CrossRefPubMedGoogle Scholar
  32. 32.
    • Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hep. 2016;23(12):994–1002. This prospective study of 54 cirrhotic patients used noninvasive measurements of fibrosis and portal hypertension with transient liver elastography and spleen and liver acoustic radiation force impulse before and after IFN free DAA therapy. Liver stiffness but not spleen stiffness improved after achieving SVRGoogle Scholar
  33. 33.
    • Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65(4):692–9. This retrospective study of 56 patients measured HVPG prior to treatment with IFN free regimens. Despite the presence or absence of portal hypertension, an SVR rate of 96% was noted with associated improvement in platelet count, liver stiffness, albumin, and prothrombin time. This study is the first to demonstrate IFN free regimens are able to overcome the negative effects of portal hypertension on viral responseGoogle Scholar
  34. 34.
    Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class a hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51(6):2069–76.CrossRefPubMedGoogle Scholar
  35. 35.
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, et al. Sustained Virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–87.CrossRefPubMedGoogle Scholar
  36. 36.
  37. 37.
    Petta S, Maida M, Macaluso FS, Barbara M, Licata A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology. 2016;150:145–55.CrossRefPubMedGoogle Scholar
  38. 38.
    Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38:50–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416–23.CrossRefPubMedGoogle Scholar
  40. 40.
    Vanni E, Abate ML, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009;50:697–706.CrossRefPubMedGoogle Scholar
  41. 41.
    Burman BE, Bacchetti P, Ayala CE, et al. Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection. Liver Int. 2015;35:101–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008;49:9–16.CrossRefPubMedGoogle Scholar
  43. 43.
    Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739–44.CrossRefPubMedGoogle Scholar
  44. 44.
    Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients:a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415–23.CrossRefPubMedGoogle Scholar
  45. 45.
    Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495–503.CrossRefPubMedGoogle Scholar
  46. 46.
    Fiorino S, Bacchi-Reggiani L, de Biase D, Fornelli A, Masetti M, et al. Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review. World J Gastroenterol. 2015;21(45):12896–953.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Xu JH, Fu JJ, Wang XL, Zhu JY, Ye XH, Chen SD. Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013;19:4234–41.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Xing S, Li ZW, Tian YF, Zhang LM, Li MQ, Zhou P. Chronic hepatitis virus infection increases the risk of pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat Dis Int. 2013;12:575–83.CrossRefPubMedGoogle Scholar
  49. 49.
    Gisbert J, Garcia-Buey L, Pajares J, et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma.: systematic review and meta-analysis. Gastroenterology. 2003;125(6):1723–32.CrossRefPubMedGoogle Scholar
  50. 50.
    Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120:1034–41.CrossRefPubMedGoogle Scholar
  51. 51.
    Kwok RM, Tram TT. Hepatitis B and risk of non–hepatocellular carcinoma malignancy. Clin Liver Dis. 2016;20:693–702.CrossRefPubMedGoogle Scholar
  52. 52.
    Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23(3):468–73.CrossRefPubMedGoogle Scholar
  53. 53.
    Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347(2):89–94.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2017

Authors and Affiliations

  1. 1.Division of Gastroenterology/HepatologyWalter Reed National Military Medical CenterBethesdaUSA
  2. 2.Cedars-Sinai Medical Center Liver TransplantationLos AngelesUSA

Personalised recommendations